Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01094093




Registration number
NCT01094093
Ethics application status
Date submitted
25/03/2010
Date registered
26/03/2010
Date last updated
10/05/2021

Titles & IDs
Public title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
Secondary ID [1] 0 0
20080767
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 139

Experimental: Part B - Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).

Experimental: Part A - Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.


Treatment: Drugs: AMG 139
Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139
Timepoint [1] 0 0
16-24 weeks
Secondary outcome [1] 0 0
Characterization of the pharmacokinetics (PK) of AMG 139
Timepoint [1] 0 0
16-24 weeks
Secondary outcome [2] 0 0
Psoriasis Activity and Severity Index (PASI) scores (Part B only)
Timepoint [2] 0 0
16-24 weeks

Eligibility
Key inclusion criteria
Part A - Healthy Volunteers:

- Healthy male or female of non-reproductive potential subjects between 18 to 45
years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination, clinical laboratory values, and
ECG

- Additional inclusion criteria apply

Part B - Psoriasis Subjects:

- Male or female of non-reproductive potential subjects with PsO between 18 to 55
years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination (PE), clinical laboratory values,
and ECG; clinically acceptable PE includes evidence of moderate to severe plaque PsO

- Diagnosis of plaque PsO for at least 6 months

- Moderate to severe plaque PsO defined by:

- A minimum PASI score of = 10

- Psoriasis involving = 10% of the Body Surface Area (BSA)

- Additional inclusion criteria apply
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Parts A - Healthy Volunteers:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- History of malignancy of any type, other than in situ cervical cancer or surgically
excised non-melanomatous skin cancers in past 5 years

- Additional exclusion criteria apply

Part B - Psoriasis Subjects:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- Guttate, pustular, or other non-plaque forms of PsO

- Evidence of skin conditions other than PsO (eg, eczema) that would interfere with
evaluations of the effect of investigational product on psoriasis

- History of malignancy of any type, other than in situ cervical cancer or surgically
excised non-melanomatous skin cancers in past 5 years

- Additional exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/04/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/07/2011
Sample size
Target
Accrual to date
Final
73
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network Limited - Melbourne
Recruitment hospital [2] 0 0
Clinical Medical and Analytical eXcellence (CMAX) - Adelaide
Recruitment hospital [3] 0 0
QPharm Pty Limited - Herston
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment postcode(s) [2] 0 0
SA500 - Adelaide
Recruitment postcode(s) [3] 0 0
4006 - Herston
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Grafton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and tolerability of AMG 139 following
single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and
subjects with moderate to severe psoriasis (PsO).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01094093
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01094093